In a larger cohort of 724 patients with prostate cancer, Ayala and colleagues observed significantly decreased levels of stromal Cav-1 in concordance with increased Gleason score (P = 0.012) and reduced relapse-free survival (P = 0.009) [111]. This evidence concerns the gene CAV1 and prostate cancer.